← Back to patent-cliff list
Atuliflapon
Tier C — Watch / tradeAtuliflapon
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ALOX5AP
Indications (approved)：Asthma, Kidney disease, Acute coronary syndrome, Chronic renal impairment, Coronary artery lesion
Regional status
US
Phase II
2020-10-01
EU
Phase II
2017-10-30
China
Phase I
2022-10-12
Japan
Phase II
2020-10-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atuliflapon?
Approved indications include: Asthma, Kidney disease, Acute coronary syndrome, Chronic renal impairment, Coronary artery lesion.
When does the Atuliflapon patent expire?
No public expiry year is available for Atuliflapon yet; this page updates once verified.
How do I get a quote for Atuliflapon intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09